Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
暂无分享,去创建一个
Michael L. Wang | A. Hui | A. Jakubowiak | S. Lonial | J. Laubach | P. Richardson | M. Talpaz | A. Di Bacco | R. Harvey | R. Baz | N. Gupta | D. Berg | Guohui Liu | Jiang Yu